No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Fagron N.V. operates as a pharmaceutical compounding enterprise, dedicated to providing customized medicinal solutions for hospitals, pharmacies, clinics, and individual patients. The company is actively involved in developing innovative concepts, delivery systems, and formulations within the compounding sector. Its extensive offerings encompass essential raw materials, specialized equipment, semi-finished products, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Additionally, through the Fagron Academy, the firm delivers educational and training programs to healthcare prescribers and pharmacists. With a significant global footprint, Fagron conducts operations across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company adopted its current name, Fagron NV, in January 2015, having previously been known as Arseus NV.
www.fagron.comNo one on the platform currently holds FAGR.BR.
No tracked institution reports a position in FAGR.BR as of their last filing.
No one on the platform has traded FAGR.BR yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 13.0% | 12.5% | — | — | — | |
| Rev. Growth % | 9.2% | 11.4% | ||||
| Profit Margin % | 9.6% | 9.8% | 8.5% | |||
| Free Cash Flow Margin % | 11.9% | 10.8% | 11.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.1B | +20.0% | $1.45 | $1.31–$1.68 | — | 5 |
| 2027 | $1.2B | +8.4% | $1.63 | $1.47–$1.84 | — | 5 |
| 2028 | $1.3B | +7.6% | $1.86 | $1.71–$2.09 | — | 5 |
| 2029 | $1.5B | +16.2% | $2.44 | $2.40–$2.52 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| +0.95% |
| $119M |
| — |
| IBAB.BRIon Beam Applications S.A. | $15.42 | -0.26% | $452M | — |
| ONWD.BROnward Medical N.V. | $2.73 | -0.18% | $127M | — |
Source: Financial Modeling Prep · peers by sector/industry